483 related articles for article (PubMed ID: 19783811)
1. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Cipriani S; Mencarelli A; Palladino G; Fiorucci S
J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811
[TBL] [Abstract][Full Text] [Related]
2. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
[TBL] [Abstract][Full Text] [Related]
3. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
Ma Y; Huang Y; Yan L; Gao M; Liu D
Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
[TBL] [Abstract][Full Text] [Related]
4. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
6. Antiatherosclerotic effect of farnesoid X receptor.
Mencarelli A; Renga B; Distrutti E; Fiorucci S
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
Zhang HM; Wang X; Wu ZH; Liu HL; Chen W; Zhang ZZ; Chen D; Zeng TS
Mol Med Rep; 2016 Mar; 13(3):2135-42. PubMed ID: 26782298
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
[TBL] [Abstract][Full Text] [Related]
11. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
12. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
13. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats.
Tovar AR; Torre-Villalvazo I; Ochoa M; Elías AL; Ortíz V; Aguilar-Salinas CA; Torres N
J Lipid Res; 2005 Sep; 46(9):1823-32. PubMed ID: 15995177
[TBL] [Abstract][Full Text] [Related]
14. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Gai Z; Gui T; Hiller C; Kullak-Ublick GA
J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
[TBL] [Abstract][Full Text] [Related]
16. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Kuhlmann J; Neumann-Haefelin C; Belz U; Kalisch J; Juretschke HP; Stein M; Kleinschmidt E; Kramer W; Herling AW
Diabetes; 2003 Jan; 52(1):138-44. PubMed ID: 12502504
[TBL] [Abstract][Full Text] [Related]
17. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
Chakrabarti R; Vikramadithyan RK; Kumar MP; Kumar SK; Mamidi NV; Misra P; Suresh J; Hiriyan J; Rao CS; Rajagopalan R
Diabetes Obes Metab; 2002 Sep; 4(5):319-28. PubMed ID: 12190995
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Expression Reduced in Obese Rat Model With Insulin Resistance.
Pang S; Yu L; Lu Y; Jiang Q; Hou L; Shi R; Ding L; Wang C; Duan G
Am J Med Sci; 2015 Dec; 350(6):467-70. PubMed ID: 26488943
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
20. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
